Speaker illustration

Professor Michael Ezekowitz

Thomas Jefferson University Hospital, Philadelphia (United States of America)

Member of:

European Society of Cardiology

RESEARCH INTERESTS • Design and conduct clinical trials, in patients with Atrial Fibrillation • The Evaluation of Novel Anticoagulants, Antiarythmic Agents and Devices Involved in the Treatment and the Management of Atrial Fibrillation RECENT AWARDS • 2014/2015 Thompson Reuters top 1% Clinical Scientist in the World based upon impact of publications at MLH / LIMA • 2016 First Heart Rhythm Institute Distinguished Visiting Professor at the University of Oklahoma Health Science Center • Best scientific Paper of 2009 and 2011. Awarded by AHA • 2018 NSAID paper in top 5% of all research outputs ever tracked by Altmetric, out of over 11 million • Circulation: Arrhythmia and Electrophysiology 2018 Silver Reviewer Recognition Award. • 2019 Top 1% of Experts in Atrial Fibrillation Based article since 2009 • Provided Care to 2 US Presidents • High school Westville Boys High, Pro meritus award (highest award given by school)

Stroke, atrial fibrillation and anticoagulation

Event: ESC Congress 2018

Topic: Stroke Prevention

Session type: Symposium

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb